Search
2023_Company_profile_232103_ENG.pdf
Effect_of_Tiotropium_and_Salmeterol_in_COPD_Patients_With .pdf
Risk Factors of Venous Thromboembolism (VTE)_0.pdf
Prevalence of AF worldwide.pdf
Boehringer_Ingelheim_Company_Profile_2015.pdf
infographic.global_burden_of_cv_diease.pdf
Boehringer_Ingelheim_Company_Profile_2015.pdf
Prevention-and-Treatment-of-Diabetic-and-Cardiovascular-Complications-in-Kenya.pdf
20181130_BI Office Hours-Vienna_flyer_final.pdf
Boehringer_Ingelheim_Company_Profile_2019.pdf
office_hours_london.pdf
Symptoms of VTE.pdf
Advancing_Anticoagulation_Care_Professor_Levy_Opinion_Piece.pdf
Boehringer_Ingelheim_company_profile_2015.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
Emmanuelle leads a team of scientists
Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Ingelvac CircoFLEX
For the active immunisation of pigs over the age of two weeks against porcine circovirus type 2 to reduce mortality, clinical signs – including weight loss – and lesions in lymphoid tissues associated with porcine circovirus diseases (PCVD).
Ingelvac MycoFLEX®
For the active immunisation of pigs from the age of three weeks to reduce lung lesions following infections with Mycoplasma hyopneumoniae.
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Informed decision and safe use of medications
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines